Shares of MediGene AG (ETR:MDG1) traded up 1.3% during trading on Wednesday . The company traded as high as €5.71 ($6.63) and last traded at €5.61 ($6.52), 43,905 shares traded hands during mid-day trading. A decline of 86% from the average session volume of 306,207 shares. The stock had previously closed at €5.54 ($6.44).
Separately, Baader Bank set a €11.00 ($12.79) target price on shares of MediGene and gave the company a “neutral” rating in a research note on Wednesday, November 13th.
The stock has a 50 day simple moving average of €5.72 and a 200 day simple moving average of €6.61. The company has a market cap of $138.29 million and a price-to-earnings ratio of -5.77. The company has a quick ratio of 5.10, a current ratio of 5.10 and a debt-to-equity ratio of 7.43.
MediGene Company Profile (ETR:MDG1)
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.
Further Reading: What is the Beige Book?
Receive News & Ratings for MediGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene and related companies with MarketBeat.com's FREE daily email newsletter.